DSM’s microbial fermentation CMO business unit and UK-based biopharmaceutical company, PolyTherics, have formed an agreement to develop and manufacture PolyTherics’ lead ‘biobetter’ product, HiPEG IFN a-2a.
Dutch chemicals giant DSM and France’s LibraGen are targeting the chemical and pharmaceutical industries with their new chiral amine production accord, which aims to develop a range of new catalytic enzymes.
A year after it published its five-year strategy: Vision 2010 -
Building on Strengths - DSM's commitment is showing no sign of
slowing as is continues to invest in the expansion of its
pharmaceutical production capabilities around...
Chemicals and nutrition group DSM has reported strong profits for
the first quarter in 2006, including in its pharma business, as
higher prices and lower costs have helped it overcome the increase
in raw material costs.
Rising prices globally have helped Dutch chemicals manufacturer DSM
go back to profit in Q4, up to €112m (€134m) from €3m in the red a
year ago, with operating profits in its Life Science division
almost doubling to €39m, albeit thanks...
A restructure of DSM's pharma businesses will see the closure of
its Pharma Chemicals site in Michigan, US, in the first half of
2007 and the mothballing of the DSM Biologics facilities in
Montreal, Canada at the beginning of...
DSM announced that higher margins and lower fixed costs had boosted
operating profits by 44 per cent to €220 million in the third
quarter, with the performance materials and industrial chemicals
divisions leading the increase.
Dutch group DSM, one of Europe's top three ingredient suppliers to
drug makers, increased sales of pharma products during the second
quarter but continued losses from the antibiotics market halved the
Life Sciences operating...
DSM Anti-Infectives, the world's largest producer of antibiotics,
is planning to expand a manufacturing plant for a key intermediate
used in the manufacture of cephalosporins that will make it the
largest producer of the compound...
DSM will cut around 500 jobs at its Chemelot site in Geleen, the
Netherlands over the next two years, in an effort to cut costs by
over €50 million per annum. The jobs will largely go in support
services and manufacturing staff departments.
DSM reports a disappointing set of second quarter results and says
it is unlikely to meet its 2002 operating profit level this year;
the group blames weaker demand for its products and negative
currency factors. Restructuring drive...
In the second news of the day on a European life science company,
DSM announced this week that from now on it will supply
technologies and services for the initial development phases of new
medicines - supplementing its existing service...